Drug Discovery World

SEPTEMBER 12, 2022

As the biopharmaceutical industry increases its focus on developing RNA therapeutics, the new RNA solution could help R&D organisations accelerate the delivery of drug candidates. The post New solution to boost RNA drug development appeared first on Drug Discovery World (DDW).

RNA 130

RNA Drug Development Vaccine Drugs 130

Drug Discovery World

DECEMBER 13, 2022

Japanese researchers propose using RNA interference for correcting a mistake in the genetic code of patients with Fukuyama muscular dystrophy. . Using RNA interference, researchers restored the normal biological function of FKTN in patient-derived cells, offering hope for a new therapy. . Modifying RNA function.

RNA 130

RNA DNA Clinical Trials Therapies 130

Drug Discovery World

APRIL 11, 2023

US-based start-up Atomic AI is using artificial intelligence (AI) to design more intelligent RNA-targeted and RNA-based medicines. As tech experts call for improved regulation and a halt to the development of AI, we take a look at how one company, Atomic AI, is using it to develop RNA-targeting treatments for a range of diseases.

RNA 130

RNA Small Molecule Engineering Disease 130

Drug Discovery World

JANUARY 10, 2023

This collaboration aims to further exploit circRNAs by developing a novel mechanism to facilitate RNA circularisation specifically in colorectal cancer cells. The post Alliance to develop circular RNA-based therapeutics appeared first on Drug Discovery World (DDW).

RNA 130

RNA Vaccine Therapies Drugs 130

Drug Discovery World

AUGUST 1, 2023

Investigators at the Icahn School of Medicine at Mount Sinai have designed an RNA-based strategy to activate dendritic cells that eradicated tumours and prevented their recurrence in mouse models of melanoma. Dendritic cells have been a key focus for the development of new cancer therapies as these cells organise the cancer-immunity cycle.

RNA 130

RNA Clinical Trials Research Trials 130

Drug Discovery World

AUGUST 22, 2024

She discusses with DDW’s Megan Thomas the company’s lead programme; a gene therapy called ER-100. Life Biosciences’ gene therapy approach differs from traditional gene replacement and gene editing approaches in that the company are not altering the DNA sequence.

Therapies 148

Therapies DNA Disease RNA 148

Drug Discovery World

FEBRUARY 27, 2023

DDW’s Diana Spencer speaks to Raphael Townshend PhD, Founder and CEO of Atomic AI, about the company’s successes so far, plans for the future and the unique approach of combining RNA structural biology and AI models. DS: How is Atomic AI “unlocking the next generation of RNA drug discovery”? What is unique about your engine?

RNA 130

RNA Science Small Molecule Engineering 130

Drug Discovery World

DECEMBER 16, 2022

The investment allows the company to focus on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases. . The post Biotech company raises $30M to target RNA modifying enzymes appeared first on Drug Discovery World (DDW).

RNA 130

RNA Immune Response Small Molecule Therapies 130

Drug Discovery World

SEPTEMBER 6, 2024

Eli Lilly and biotechnology company HAYA Therapeutics have announced a multi-year agreement to apply HAYA’s RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions. The company’s lead therapeutic candidate is HTX-001, in development for the treatment of heart failure.

RNA 148

RNA Treatment Disease Therapies 148

Drug Discovery World

JANUARY 31, 2024

Mark Treherne will talk about advanced therapies and the development of RNA gene therapy for aggressive cancers which is being carried out at Spliceor. Doug Danison will discuss transitioning innovative science into commercial success in the areas of CGTs.

Therapies 130

Therapies RNA Science Marketing 130

Drug Discovery World

FEBRUARY 15, 2024

Mark Treherne will talk about advanced therapies and the development of RNA gene therapy for aggressive cancers which is being carried out at Spliceor.

Therapies 130

Therapies RNA Science Marketing 130

Drug Discovery World

FEBRUARY 5, 2024

Mark Treherne will talk about advanced therapies and the development of RNA gene therapy for aggressive cancers which is being carried out at Spliceor. Doug Danison will discuss transitioning innovative science into commercial success in the areas of CGTs.

Therapies 130

Therapies Marketing RNA Science 130

Drug Discovery World

FEBRUARY 22, 2024

Mark Treherne will talk about advanced therapies and the development of RNA gene therapy for aggressive cancers which is being carried out at Spliceor. Doug Danison will discuss transitioning innovative science into commercial success in the areas of CGTs.

Therapies 130

Therapies RNA Science Marketing 130

Drug Discovery World

FEBRUARY 13, 2024

In this webinar, hosted by DDW and sponsored by Astrea Bioseparations, you will learn about how market growth can be sustained to maximise on opportunities in cell and gene therapy (CGT). Mark Treherne will talk about advanced therapies and the development of RNA gene therapy for aggressive cancers which is being carried out at Spliceor.

Therapies 130

Therapies Marketing RNA Science 130

BioPharma Drive: Drug Pricing

SEPTEMBER 5, 2023

The biotech, one of several advancing RNA editing medicines, expects to obtain “proof-of-mechanism” data in patients with the inherited disorder alpha-1 antitrypsin deficiency by next year.

RNA 73

RNA Therapies 73

Drug Discovery World

MARCH 25, 2024

Cardior is focused on the discovery and development of therapies that target RNA to prevent, repair and reverse diseases of the heart. The company seeks to advance a novel class of antisense oligonucleotides (ASOs) targeting non-coding RNAs (ncRNAs) that act on several key disease pathways simultaneously. “We

Therapies 130

Therapies RNA Disease Trials 130

Drug Target Review

DECEMBER 6, 2023

Dear readers, RNA, or ribonucleic acid, plays a pivotal role in the intricate dance of cellular processes. We are committed to providing you with the highest quality content, and we believe that this report will deliver a different perspective on the topics covered.

RNA 52

RNA DNA Vaccine Science 52

Drug Discovery World

AUGUST 16, 2023

Cancers evolve between therapy and recurrence The researchers also explored whether immune signatures were conserved between primary tumour samples and secondary tumour samples taken after the cancer had become metastatic.

Therapies 130

Therapies RNA DNA Clinical Trials 130

Drug Discovery World

JULY 3, 2024

As a result, the data provides an important proof-of-concept for Circio’s circular RNA platform, which we expect will translate into improved gene therapies for patients in the future,” said Dr Thomas Hansen, CTO at Circio. “In In parallel, we have deployed machine learning to optimise circVec sequence composition.

RNA 148

RNA Protein Expression Therapies Drugs 148

Drug Discovery World

MARCH 7, 2024

Ginkgo Bioworks has acquired Patch Biosciences, with the intention to strengthen its gene therapy services, cell therapy services, and RNA therapeutics services. The collaboration achieved its goals of enhancing the AAV production titres of Biogen’s gene therapy manufacturing processes.

RNA 130

RNA Engineering Therapies Virus 130

Drug Discovery World

MAY 16, 2023

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to SiSaf’s small interfering RNA (siRNA) therapeutic for skeletal disorder Autosomal Dominant Osteopetrosis Type 2 (ADO2). The post Therapy for rare skeletal disorder granted orphan status appeared first on Drug Discovery World (DDW).

Therapies 130

Therapies Clinical Trials RNA FDA 130

Drug Target Review

JUNE 15, 2023

In this article Drug Target Review’s Izzy Wood spoke to Sam Hasson, Director of Target Biology at Rgenta Therapeutics, a biotech firm in Massachusetts, US, that aims to develop small molecule therapeutics to target RNA processing. The field is faced with a number of obstacles that require specifically assay technologies to surmount.

RNA 96

RNA Small Molecule Disease Assay Development 96

Drug Target Review

AUGUST 28, 2024

Once a patient develops advanced cirrhosis/end-stage liver disease there are no specific therapies to significantly avoid major decompensations and death in the next few years. Could you describe the platform of macrophage biology and cell engineering used by Resolution Therapeutics in developing their cell therapies?

Therapies 114

Therapies Disease Engineering Medical Schools 114

Drug Discovery World

AUGUST 7, 2024

The grant will fund a collaboration that combines scientific expertise with machine vision tools with an aim to streamline the synthesis, purification and analysis of RNA medicines. The partnership between CatSci and Reach Industries will leverage AI and machine learning tools to accelerate the development of oligonucleotide therapies.”

RNA 148

RNA Government Therapies Science 148

Drug Discovery World

MAY 21, 2024

Takara Bio has launched PrimeCap T7 RNA Polymerase (low dsRNA), a mutant T7 RNA polymerase suitable for mRNA therapeutic research and development. ” PrimeCap T7 RNA Polymerase is currently available in research grade, however, the company has announced plans to release a GMP version of the enzyme shortly.

Production 148

Production RNA Engineering Therapies 148

Drug Discovery World

JUNE 13, 2024

The new study investigated what happens when metformin, a type 2 diabetes medication, is used to treat colorectal cancer cells, in the process demonstrating that it could be exploited to develop new cancer therapies.

RNA 130

RNA Therapies Treatment Regulations 130

Drug Target Review

NOVEMBER 29, 2023

Our primary focus is to design and develop RNA therapies for liver diseases. Our team of chemists then uses this information to develop novel therapies. By doing this, we get a superior understanding of which therapies will and will not work in human biology before a clinical trial.

Therapies 102

Therapies Disease RNA Engineering 102

Drug Discovery World

JUNE 9, 2023

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to DTx Pharma’s DTx-1252, an investigational small interfering RNA (siRNA) therapeutic for the treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A). “We are pleased to receive Orphan Drug Designation from the FDA for DTx-1252.

Disease 130

Disease Therapies FDA RNA 130

Drug Target Review

MAY 22, 2024

What are the key findings of Circio’s in vivo proof-of-concept for its circVec circular RNA platform technology compared to conventional mRNA-based expression with DNA vectors? Circular RNA (circRNA) has two major advantages versus mRNA in a vector-expression context.

Therapies 59

Therapies RNA Protein Expression DNA 59

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. million price point per dose.

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

Drug Discovery World

MAY 17, 2024

From a weight loss drug that prevents heart attacks and a gene therapy that restores hearing, to a vaccine that can treat viruses that don’t exist yet, our chosen news stories this week all represent potential breakthroughs in their respective fields.

Therapies 130

Therapies Vaccine RNA Clinical Trials 130

Drug Discovery World

JANUARY 27, 2023

Cell and gene therapies have been making the news this week, as we launch our very own guide to global innovation in CGT with the Winter issue of DDW, as well as an exciting new virtual event on the same topic. News round-up for 23-27 January by DDW Digital Content Editor Diana Spencer.

RNA 130

RNA Therapies Drugs Virus 130

Drug Discovery World

NOVEMBER 7, 2022

Genomic healthcare data is critical to identify disease risk, ancestry, traits and response to medicines and aids in the development of new targeted therapies – precision medicines. The post Why genomic healthcare data matters in the development of new therapies appeared first on Drug Discovery World (DDW). The origins .

Therapies 246

Therapies DNA Disease Research 246

Drug Discovery World

AUGUST 30, 2024

The investment from Innovate UK will drive both early and later stage innovations in cancer therapies, building on UK economic potential in this field. Together, this portfolio of investments will diversify the pipeline of targeted, safe and effective therapies for cancer patients.”

DNA 148

DNA Drugs RNA Therapies 148

Drug Discovery World

FEBRUARY 13, 2023

SB: Transcriptomics is the study of genomic RNA transcripts in a biological system. RNA transcript expression levels can provide insight into underlying biology – eg. In terms of technical process, traditional RNA sequencing was a very laborious process that could take several weeks and was prone to errors. SB: Absolutely.

RNA 130

RNA Drugs Immune Response Therapies 130

Drug Discovery World

JANUARY 11, 2024

Researchers have used messenger RNA (mRNA) to create an effective therapy for a rare liver disease in preclinical studies, demonstrating the technology’s potential therapeutic use in people. Successful industry/academia collaboration Fewer than 5% of rare diseases have approved therapies and most of these treatments use gene therapy.

Disease 148

Disease Research RNA Therapies 148

Alta Sciences

APRIL 16, 2024

Inside The Altascientist: The Benefits of PCR for Your Gene Therapy Programs pmjackson Tue, 04/16/2024 - 19:04 The gene therapy landscape continues to accelerate in preclinical and clinical research, with programs constantly in development for targeted, personalized medicines. But how are PCR analysis techniques applied?

Therapies 52

Therapies DNA RNA Laboratories 52